Drug
Vorapaxar clinical trials
Also written Zontivity and SCH 530348.
- studies test it
- 15
- open now
- 0
- in phase 3
- 3
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Development codes
Combined with it in one product
Studies by the year they started
15 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 3
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 8
Merck Sharp & Dohme LLC (7) · University of Florida (2) · Inova Health Care Services (1) · Medical University of Vienna (1) · Kirby Institute (1) · Ken Mahaffey (1) · North Texas Veterans Healthcare System (1) · Vanderbilt University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vorapaxar is read from its arms, and is right about nine times in ten.
Testing it · 15
- Vorapaxar on Thrombin Generation and CoagulabilityCompletedPhase 4Inova Health Care ServicesNCT03207451Written as Vorapaxar
- Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and TicagrelorCompletedPhase 4University of FloridaNCT02545933Written as Vorapaxar
- Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes MellitusCompletedPhase 4University of FloridaNCT02548650Written as Vorapaxar
- Vorapaxar in the Human Endotoxemia ModelCompletedPhase 4Medical University of ViennaNCT02875028Written as Vorapaxar
- Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation EndpointsCompletedPhase 1/2Kirby InstituteNCT02394730Written as vorapaxar
- Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis AccessCompletedPhase 2Ken MahaffeyNCT02475837Written as Vorapaxar sulfate
- Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)CompletedPhase 3Merck Sharp & Dohme LLCNCT00526474Written as Vorapaxar
- Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)CompletedPhase 3Merck Sharp & Dohme LLCNCT00617123Written as Vorapaxar 2.5 mg
- Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)CompletedPhase 2Merck Sharp & Dohme LLCNCT00684515Written as Vorapaxar 2.5 mg
- Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)TerminatedPhase 3Merck Sharp & Dohme LLCNCT00527943Written as Vorapaxar
- Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)Status unknownPhase 4North Texas Veterans Healthcare SystemNCT02660866Written as Vorapaxar 2.08 mg/d + background APT + SMT.
- Vorapaxar and Lower Extremity Bypass GraftsWithdrawnPhase 4Vanderbilt UniversityNCT02975583Written as Vorapaxar
- Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)CompletedPhase 2Merck Sharp & Dohme LLCNCT00132912Written as SCH 530348
- Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)CompletedPhase 2Merck Sharp & Dohme LLCNCT00684203Written as Vorapaxar
- A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)CompletedPhase 1Merck Sharp & Dohme LLCNCT01358344Written as SCH 530348 (high percentage)
Codes
What other systems call vorapaxar · ClinicalTrials.gg INT005292
- MeSH (NLM) C530299vorapaxarConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ZCE93644N2VORAPAXARConfirmed FDA, NLM, Wikidata
- RxNorm 1537034Confirmed FDA, Wikidata
- Wikidata Q7941753vorapaxarConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152912VorapaxarOne source FDA
- DrugBank DB09030One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C530299 | vorapaxar | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ZCE93644N2 | VORAPAXAR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1537034 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7941753 | vorapaxar | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152912 | Vorapaxar | One source FDA |
| DrugBank | DB09030 | — | One source Wikidata |
Also registered as vorapaxar sulfate (UNII IN66038E6C · RxNorm 1537050).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.